Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 24, 2009
Mon, February 23, 2009 GTC Biotherapeutics to Host Fourth Quarter and Year End 2008 Earnings Call and Webcast on Friday, February 27, 2009
FRAMINGHAM, Mass.--([ BUSINESS WIRE ])--GTC Biotherapeutics, Inc. (Nasdaq:GTCB) ("GTC") announced today that its financial results for the fourth quarter and year-end 2008 will be released on Friday, February 27, 2009 followed by a webcast conference call starting at 10:00 a.m. Eastern Time. You may access the live Internet broadcast or the subsequent archived recording, on GTC's website at [ http://www.gtc-bio.com ] or access the conference call as follows:
Live Call – In the United States, dial 1-888-713-4215
Outside the United States, dial 617-213-4867
Reference call ID: when prompted 57945237
Audio Archive – In the United States, dial 888-286-8010
Outside the United States, dial 617-801-6888
Reference call ID: when prompted 76483340
Participants may pre-register for the call at: [ https://www.theconferencingservice.com/prereg/key.process?key=PRRD4QY9E ].
Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.
NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until March 25, 2009.
The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at [ www.earnings.com ] or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents ([ www.streetevents.com ]).
About GTC Biotherapeutics
GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC's recombinant human antithrombin, has been approved for use in the United States and Europe. ATryn® is the first and only transgenically produced product to be approved for therapeutic use anywhere in the world. In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa, VIII, and IX, which are being developed for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, [ http://www.gtc-bio.com ].
